 | • レポートコード：MRC2-11QY13025 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はウイルス性結膜炎パイプライン薬剤のグローバル市場について調査・分析したレポートです。種類別（急性濾胞性結膜炎パイプライン薬剤、亜急性・慢性結膜炎パイプライン薬剤）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ウイルス性結膜炎パイプライン薬剤の競争状況、市場シェア ・世界のウイルス性結膜炎パイプライン薬剤市場：種類別市場規模 2015年-2020年（急性濾胞性結膜炎パイプライン薬剤、亜急性・慢性結膜炎パイプライン薬剤） ・世界のウイルス性結膜炎パイプライン薬剤市場：種類別市場規模予測 2021年-2026年（急性濾胞性結膜炎パイプライン薬剤、亜急性・慢性結膜炎パイプライン薬剤） ・世界のウイルス性結膜炎パイプライン薬剤市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界のウイルス性結膜炎パイプライン薬剤市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米のウイルス性結膜炎パイプライン薬剤市場分析：米国、カナダ ・ヨーロッパのウイルス性結膜炎パイプライン薬剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのウイルス性結膜炎パイプライン薬剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のウイルス性結膜炎パイプライン薬剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのウイルス性結膜炎パイプライン薬剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Panoptes Pharma GES.M.B.H.、Takeda、Allergan Plc、Novartis AG、NovaBay Pharmaceuticals Inc.、Adenovir Pharma AB、NicOx S.A.、NanoViricides Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Viral Conjunctivitis Pipeline Drugs Market
The global Viral Conjunctivitis Pipeline Drugs market size is projected to reach US$ 51 million by 2026, from US$ 36 million in 2020, at a CAGR of 39.5%% during 2021-2026.
Global Viral Conjunctivitis Pipeline Drugs Scope and Market Size
Viral Conjunctivitis Pipeline Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Viral Conjunctivitis Pipeline Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Viral Conjunctivitis Pipeline Drugs market is segmented into
Acute Follicular Conjunctivitis Pipeline Drugs
Subacute Or Chronic Conjunctivitis Pipeline Drugs
Segment by Application, the Viral Conjunctivitis Pipeline Drugs market is segmented into
Hospitals
Clinics
Others
Regional and Country-level Analysis
The Viral Conjunctivitis Pipeline Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Viral Conjunctivitis Pipeline Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Viral Conjunctivitis Pipeline Drugs Market Share Analysis
Viral Conjunctivitis Pipeline Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Viral Conjunctivitis Pipeline Drugs business, the date to enter into the Viral Conjunctivitis Pipeline Drugs market, Viral Conjunctivitis Pipeline Drugs product introduction, recent developments, etc.
The major vendors covered:
Panoptes Pharma GES.M.B.H.
Takeda
Allergan Plc
Novartis AG
NovaBay Pharmaceuticals Inc.
Adenovir Pharma AB
NicOx S.A.
NanoViricides Inc.
1 Study Coverage
1.1 Viral Conjunctivitis Pipeline Drugs Product Introduction
1.2 Market Segments
1.3 Key Viral Conjunctivitis Pipeline Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Viral Conjunctivitis Pipeline Drugs Market Size Growth Rate by Type
1.4.2 Acute Follicular Conjunctivitis Pipeline Drugs
1.4.3 Subacute Or Chronic Conjunctivitis Pipeline Drugs
1.5 Market by Application
1.5.1 Global Viral Conjunctivitis Pipeline Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Viral Conjunctivitis Pipeline Drugs Market Size, Estimates and Forecasts
2.1.1 Global Viral Conjunctivitis Pipeline Drugs Revenue 2015-2026
2.1.2 Global Viral Conjunctivitis Pipeline Drugs Sales 2015-2026
2.2 Global Viral Conjunctivitis Pipeline Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Viral Conjunctivitis Pipeline Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Viral Conjunctivitis Pipeline Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Viral Conjunctivitis Pipeline Drugs Competitor Landscape by Players
3.1 Viral Conjunctivitis Pipeline Drugs Sales by Manufacturers
3.1.1 Viral Conjunctivitis Pipeline Drugs Sales by Manufacturers (2015-2020)
3.1.2 Viral Conjunctivitis Pipeline Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Viral Conjunctivitis Pipeline Drugs Revenue by Manufacturers
3.2.1 Viral Conjunctivitis Pipeline Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Viral Conjunctivitis Pipeline Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Viral Conjunctivitis Pipeline Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Viral Conjunctivitis Pipeline Drugs Revenue in 2019
3.2.5 Global Viral Conjunctivitis Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Viral Conjunctivitis Pipeline Drugs Price by Manufacturers
3.4 Viral Conjunctivitis Pipeline Drugs Manufacturing Base Distribution, Product Types
3.4.1 Viral Conjunctivitis Pipeline Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Viral Conjunctivitis Pipeline Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Viral Conjunctivitis Pipeline Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Viral Conjunctivitis Pipeline Drugs Market Size by Type (2015-2020)
4.1.1 Global Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020)
4.1.2 Global Viral Conjunctivitis Pipeline Drugs Revenue by Type (2015-2020)
4.1.3 Viral Conjunctivitis Pipeline Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Viral Conjunctivitis Pipeline Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Viral Conjunctivitis Pipeline Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Viral Conjunctivitis Pipeline Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Viral Conjunctivitis Pipeline Drugs Market Size by Application (2015-2020)
5.1.1 Global Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020)
5.1.2 Global Viral Conjunctivitis Pipeline Drugs Revenue by Application (2015-2020)
5.1.3 Viral Conjunctivitis Pipeline Drugs Price by Application (2015-2020)
5.2 Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Viral Conjunctivitis Pipeline Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Viral Conjunctivitis Pipeline Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Viral Conjunctivitis Pipeline Drugs by Country
6.1.1 North America Viral Conjunctivitis Pipeline Drugs Sales by Country
6.1.2 North America Viral Conjunctivitis Pipeline Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Type
6.3 North America Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Viral Conjunctivitis Pipeline Drugs by Country
7.1.1 Europe Viral Conjunctivitis Pipeline Drugs Sales by Country
7.1.2 Europe Viral Conjunctivitis Pipeline Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Type
7.3 Europe Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Viral Conjunctivitis Pipeline Drugs by Region
8.1.1 Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales by Region
8.1.2 Asia Pacific Viral Conjunctivitis Pipeline Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Type
8.3 Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Viral Conjunctivitis Pipeline Drugs by Country
9.1.1 Latin America Viral Conjunctivitis Pipeline Drugs Sales by Country
9.1.2 Latin America Viral Conjunctivitis Pipeline Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Type
9.3 Central & South America Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Viral Conjunctivitis Pipeline Drugs by Country
10.1.1 Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales by Country
10.1.2 Middle East and Africa Viral Conjunctivitis Pipeline Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Viral Conjunctivitis Pipeline Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Panoptes Pharma GES.M.B.H.
11.1.1 Panoptes Pharma GES.M.B.H. Corporation Information
11.1.2 Panoptes Pharma GES.M.B.H. Description and Business Overview
11.1.3 Panoptes Pharma GES.M.B.H. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Products Offered
11.1.5 Panoptes Pharma GES.M.B.H. Related Developments
11.2 Takeda
11.2.1 Takeda Corporation Information
11.2.2 Takeda Description and Business Overview
11.2.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Takeda Viral Conjunctivitis Pipeline Drugs Products Offered
11.2.5 Takeda Related Developments
11.3 Allergan Plc
11.3.1 Allergan Plc Corporation Information
11.3.2 Allergan Plc Description and Business Overview
11.3.3 Allergan Plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Allergan Plc Viral Conjunctivitis Pipeline Drugs Products Offered
11.3.5 Allergan Plc Related Developments
11.4 Novartis AG
11.4.1 Novartis AG Corporation Information
11.4.2 Novartis AG Description and Business Overview
11.4.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novartis AG Viral Conjunctivitis Pipeline Drugs Products Offered
11.4.5 Novartis AG Related Developments
11.5 NovaBay Pharmaceuticals Inc.
11.5.1 NovaBay Pharmaceuticals Inc. Corporation Information
11.5.2 NovaBay Pharmaceuticals Inc. Description and Business Overview
11.5.3 NovaBay Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 NovaBay Pharmaceuticals Inc. Viral Conjunctivitis Pipeline Drugs Products Offered
11.5.5 NovaBay Pharmaceuticals Inc. Related Developments
11.6 Adenovir Pharma AB
11.6.1 Adenovir Pharma AB Corporation Information
11.6.2 Adenovir Pharma AB Description and Business Overview
11.6.3 Adenovir Pharma AB Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Adenovir Pharma AB Viral Conjunctivitis Pipeline Drugs Products Offered
11.6.5 Adenovir Pharma AB Related Developments
11.7 NicOx S.A.
11.7.1 NicOx S.A. Corporation Information
11.7.2 NicOx S.A. Description and Business Overview
11.7.3 NicOx S.A. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 NicOx S.A. Viral Conjunctivitis Pipeline Drugs Products Offered
11.7.5 NicOx S.A. Related Developments
11.8 NanoViricides Inc.
11.8.1 NanoViricides Inc. Corporation Information
11.8.2 NanoViricides Inc. Description and Business Overview
11.8.3 NanoViricides Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 NanoViricides Inc. Viral Conjunctivitis Pipeline Drugs Products Offered
11.8.5 NanoViricides Inc. Related Developments
11.1 Panoptes Pharma GES.M.B.H.
11.1.1 Panoptes Pharma GES.M.B.H. Corporation Information
11.1.2 Panoptes Pharma GES.M.B.H. Description and Business Overview
11.1.3 Panoptes Pharma GES.M.B.H. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Products Offered
11.1.5 Panoptes Pharma GES.M.B.H. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Viral Conjunctivitis Pipeline Drugs Market Estimates and Projections by Region
12.1.1 Global Viral Conjunctivitis Pipeline Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Viral Conjunctivitis Pipeline Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Viral Conjunctivitis Pipeline Drugs Sales Forecast (2021-2026)
12.2.2 North America: Viral Conjunctivitis Pipeline Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Viral Conjunctivitis Pipeline Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Viral Conjunctivitis Pipeline Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Viral Conjunctivitis Pipeline Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Viral Conjunctivitis Pipeline Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Viral Conjunctivitis Pipeline Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Viral Conjunctivitis Pipeline Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Viral Conjunctivitis Pipeline Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Viral Conjunctivitis Pipeline Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Viral Conjunctivitis Pipeline Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Viral Conjunctivitis Pipeline Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Viral Conjunctivitis Pipeline Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Viral Conjunctivitis Pipeline Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Viral Conjunctivitis Pipeline Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Viral Conjunctivitis Pipeline Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Viral Conjunctivitis Pipeline Drugs Market Segments
Table 2. Ranking of Global Top Viral Conjunctivitis Pipeline Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Viral Conjunctivitis Pipeline Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Acute Follicular Conjunctivitis Pipeline Drugs
Table 5. Major Manufacturers of Subacute Or Chronic Conjunctivitis Pipeline Drugs
Table 6. Global Viral Conjunctivitis Pipeline Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 7. Global Viral Conjunctivitis Pipeline Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 8. Global Viral Conjunctivitis Pipeline Drugs Sales by Regions 2015-2020 (K MT)
Table 9. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Regions (2015-2020)
Table 10. Global Viral Conjunctivitis Pipeline Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Viral Conjunctivitis Pipeline Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 12. Global Viral Conjunctivitis Pipeline Drugs Sales Share by Manufacturers (2015-2020)
Table 13. Global Viral Conjunctivitis Pipeline Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Viral Conjunctivitis Pipeline Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Viral Conjunctivitis Pipeline Drugs as of 2019)
Table 15. Viral Conjunctivitis Pipeline Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Viral Conjunctivitis Pipeline Drugs Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Viral Conjunctivitis Pipeline Drugs Price (2015-2020) (USD/MT)
Table 18. Viral Conjunctivitis Pipeline Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Viral Conjunctivitis Pipeline Drugs Product Type
Table 20. Date of International Manufacturers Enter into Viral Conjunctivitis Pipeline Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020) (K MT)
Table 23. Global Viral Conjunctivitis Pipeline Drugs Sales Share by Type (2015-2020)
Table 24. Global Viral Conjunctivitis Pipeline Drugs Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Viral Conjunctivitis Pipeline Drugs Revenue Share by Type (2015-2020)
Table 26. Viral Conjunctivitis Pipeline Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 27. Global Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020) (K MT)
Table 28. Global Viral Conjunctivitis Pipeline Drugs Sales Share by Application (2015-2020)
Table 29. North America Viral Conjunctivitis Pipeline Drugs Sales by Country (2015-2020) (K MT)
Table 30. North America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 31. North America Viral Conjunctivitis Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 33. North America Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020) (K MT)
Table 34. North America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 35. North America Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020) (K MT)
Table 36. North America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 37. Europe Viral Conjunctivitis Pipeline Drugs Sales by Country (2015-2020) (K MT)
Table 38. Europe Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 39. Europe Viral Conjunctivitis Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 41. Europe Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020) (K MT)
Table 42. Europe Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 43. Europe Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020) (K MT)
Table 44. Europe Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales by Region (2015-2020) (K MT)
Table 46. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Viral Conjunctivitis Pipeline Drugs Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020) (K MT)
Table 50. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020) (K MT)
Table 52. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 53. Latin America Viral Conjunctivitis Pipeline Drugs Sales by Country (2015-2020) (K MT)
Table 54. Latin America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Viral Conjunctivitis Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 57. Latin America Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020) (K MT)
Table 58. Latin America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 59. Latin America Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020) (K MT)
Table 60. Latin America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales by Country (2015-2020) (K MT)
Table 62. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales by Type (2015-2020) (K MT)
Table 66. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales by Application (2015-2020) (K MT)
Table 68. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 69. Panoptes Pharma GES.M.B.H. Corporation Information
Table 70. Panoptes Pharma GES.M.B.H. Description and Major Businesses
Table 71. Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 72. Panoptes Pharma GES.M.B.H. Product
Table 73. Panoptes Pharma GES.M.B.H. Recent Development
Table 74. Takeda Corporation Information
Table 75. Takeda Description and Major Businesses
Table 76. Takeda Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Takeda Product
Table 78. Takeda Recent Development
Table 79. Allergan Plc Corporation Information
Table 80. Allergan Plc Description and Major Businesses
Table 81. Allergan Plc Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. Allergan Plc Product
Table 83. Allergan Plc Recent Development
Table 84. Novartis AG Corporation Information
Table 85. Novartis AG Description and Major Businesses
Table 86. Novartis AG Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Novartis AG Product
Table 88. Novartis AG Recent Development
Table 89. NovaBay Pharmaceuticals Inc. Corporation Information
Table 90. NovaBay Pharmaceuticals Inc. Description and Major Businesses
Table 91. NovaBay Pharmaceuticals Inc. Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. NovaBay Pharmaceuticals Inc. Product
Table 93. NovaBay Pharmaceuticals Inc. Recent Development
Table 94. Adenovir Pharma AB Corporation Information
Table 95. Adenovir Pharma AB Description and Major Businesses
Table 96. Adenovir Pharma AB Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Adenovir Pharma AB Product
Table 98. Adenovir Pharma AB Recent Development
Table 99. NicOx S.A. Corporation Information
Table 100. NicOx S.A. Description and Major Businesses
Table 101. NicOx S.A. Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. NicOx S.A. Product
Table 103. NicOx S.A. Recent Development
Table 104. NanoViricides Inc. Corporation Information
Table 105. NanoViricides Inc. Description and Major Businesses
Table 106. NanoViricides Inc. Viral Conjunctivitis Pipeline Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. NanoViricides Inc. Product
Table 108. NanoViricides Inc. Recent Development
Table 109. Global Viral Conjunctivitis Pipeline Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 110. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 111. Global Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 112. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 113. North America: Viral Conjunctivitis Pipeline Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 114. North America: Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Europe: Viral Conjunctivitis Pipeline Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 116. Europe: Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Asia Pacific: Viral Conjunctivitis Pipeline Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 118. Asia Pacific: Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 119. Latin America: Viral Conjunctivitis Pipeline Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 120. Latin America: Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Middle East and Africa: Viral Conjunctivitis Pipeline Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 122. Middle East and Africa: Viral Conjunctivitis Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 124. Key Challenges
Table 125. Market Risks
Table 126. Main Points Interviewed from Key Viral Conjunctivitis Pipeline Drugs Players
Table 127. Viral Conjunctivitis Pipeline Drugs Customers List
Table 128. Viral Conjunctivitis Pipeline Drugs Distributors List
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Conjunctivitis Pipeline Drugs Product Picture
Figure 2. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Acute Follicular Conjunctivitis Pipeline Drugs Product Picture
Figure 4. Subacute Or Chronic Conjunctivitis Pipeline Drugs Product Picture
Figure 5. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application in 2020 & 2026
Figure 6. Hospitals
Figure 7. Clinics
Figure 8. Others
Figure 9. Viral Conjunctivitis Pipeline Drugs Report Years Considered
Figure 10. Global Viral Conjunctivitis Pipeline Drugs Market Size 2015-2026 (US$ Million)
Figure 11. Global Viral Conjunctivitis Pipeline Drugs Sales 2015-2026 (K MT)
Figure 12. Global Viral Conjunctivitis Pipeline Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region (2015-2020)
Figure 14. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region in 2019
Figure 15. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Region (2015-2020)
Figure 16. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Region in 2019
Figure 17. Global Viral Conjunctivitis Pipeline Drugs Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Viral Conjunctivitis Pipeline Drugs Revenue in 2019
Figure 19. Viral Conjunctivitis Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type (2015-2020)
Figure 21. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Type in 2019
Figure 22. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Type (2015-2020)
Figure 23. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Type in 2019
Figure 24. Global Viral Conjunctivitis Pipeline Drugs Market Share by Price Range (2015-2020)
Figure 25. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application (2015-2020)
Figure 26. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Application in 2019
Figure 27. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Application (2015-2020)
Figure 28. Global Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Application in 2019
Figure 29. North America Viral Conjunctivitis Pipeline Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 30. North America Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country in 2019
Figure 32. North America Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country in 2019
Figure 33. U.S. Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 34. U.S. Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. Canada Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Viral Conjunctivitis Pipeline Drugs Market Share by Type in 2019
Figure 38. North America Viral Conjunctivitis Pipeline Drugs Market Share by Application in 2019
Figure 39. Europe Viral Conjunctivitis Pipeline Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 40. Europe Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country in 2019
Figure 42. Europe Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country in 2019
Figure 43. Germany Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 44. Germany Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. France Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. U.K. Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. Italy Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Russia Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Viral Conjunctivitis Pipeline Drugs Market Share by Type in 2019
Figure 54. Europe Viral Conjunctivitis Pipeline Drugs Market Share by Application in 2019
Figure 55. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 56. Asia Pacific Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region in 2019
Figure 58. Asia Pacific Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Region in 2019
Figure 59. China Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 60. China Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. Japan Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. South Korea Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. India Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. Australia Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Taiwan Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Indonesia Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Thailand Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Malaysia Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Philippines Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Vietnam Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Share by Type in 2019
Figure 82. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Share by Application in 2019
Figure 83. Latin America Viral Conjunctivitis Pipeline Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 84. Latin America Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country in 2019
Figure 86. Latin America Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country in 2019
Figure 87. Mexico Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 88. Mexico Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Brazil Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Argentina Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Viral Conjunctivitis Pipeline Drugs Market Share by Type in 2019
Figure 94. Latin America Viral Conjunctivitis Pipeline Drugs Market Share by Application in 2019
Figure 95. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 96. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Revenue Market Share by Country in 2019
Figure 99. Turkey Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 100. Turkey Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Saudi Arabia Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Viral Conjunctivitis Pipeline Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. U.A.E Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Market Share by Type in 2019
Figure 106. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Market Share by Application in 2019
Figure 107. North America Viral Conjunctivitis Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 108. North America Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 109. Europe Viral Conjunctivitis Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. Europe Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Asia Pacific Viral Conjunctivitis Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Asia Pacific Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Latin America Viral Conjunctivitis Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Latin America Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Middle East and Africa Viral Conjunctivitis Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Porter's Five Forces Analysis
Figure 118. Channels of Distribution
Figure 119. Distributors Profiles
Figure 120. Bottom-up and Top-down Approaches for This Report
Figure 121. Data Triangulation
Figure 122. Key Executives Interviewed
ウイルス性結膜炎治療薬の世界市場（～2026年） Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely t…- 結膜炎治療薬の世界市場（～2026年） Conjunctivitis, or pink eye, is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid due to numerous causes the most common being bacterial infection. The condition is self-limiting, but in some cases results in kerato-conjunctivitis, which results in …
- 細菌性結膜炎薬の世界市場（～2026年） Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis …
- CINV既存・パイプライン治療薬の世界市場（～2026年） Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). Market Analysis and Insights: Global CINV Existing and Pipeline Drugs Market The global CINV Existing and Pipeline Drugs market size i…
- 細菌性結膜炎治療の世界市場（～2026年） Bacterial conjunctivitis is a serious eye infection caused by several types of bacteria. The aforementioned figures clarify that it is one of the most common eye problems affecting people of all ages across the U.S. Such higher prevalence of the disease definitely prompts at increasing demand for ef…